Chronology
Timeline of Abandonments, Failures, and Vindications
A dated map of cases in the archive, with each event categorized by what the evidence later showed.
Timelines can mislead when they imply inevitability. Many of these events were uncertain in real time. The point is to show how medical knowledge changes: a clue appears, a theory resists it, a claim is tested, or a regulatory pathway reshapes what can be used.
Edward Stone reports willow bark for fevers
Willow preparations were part of a long history of pain and fever remedies. Later salicylate chemistry and aspirin development transformed a plant observation into standardized pharmacology.
Semmelweis introduces chlorinated-lime hand disinfection
Mortality in his Vienna maternity ward fell dramatically, but many physicians resisted the implication that they were transmitting disease before germ theory was accepted.
Laetrile enters U.S. cancer-cure promotion
Laetrile later became a major suppressed-cure narrative. NCI reviews did not find anticancer activity in human clinical trials and documented cyanide-like toxicity risks.
Hoxsey clinics become a national alternative-cancer controversy
The Hoxsey story includes legal conflict and patient testimonials, but later case evaluations and clinical summaries do not support the treatment as an effective cancer therapy.
Thalidomide scandal transforms drug-safety regulation
The drug's teratogenic harms were catastrophic. Decades later, narrow controlled indications showed that a dangerous compound could still have specific therapeutic uses.
Tu Youyou's team isolates active artemisinin work
Ancient medical texts helped guide extraction of Artemisia annua compounds. The result became one of the most important antimalarial discoveries of the late twentieth century.
Marshall and Warren identify H. pylori's role in ulcers
Their bacterial hypothesis challenged ulcer dogma and eventually changed treatment for peptic ulcer disease when eradication therapy proved clinically meaningful.
Randomized trial supports donor-feces infusion for recurrent C. difficile
The van Nood trial was stopped early after donor-feces infusion outperformed vancomycin regimens for recurrent C. difficile infection.
FDA approves first oral fecal microbiota product for preventing recurrent C. difficile
Vowst approval showed how a once awkward procedure could move into a regulated biologic-product pathway for a specific recurrent-infection indication.
Cochrane vitamin D review shows modest, uncertain prevention evidence in young children
The review found possible slight reduction in children needing doctor or hospital visits for acute respiratory infections, but not broad proof for high-dose prevention claims.
Reading the timeline
A date is not enough to classify a remedy. Some ideas were delayed because medicine lacked the right theory or incentive structure. Others persisted after evidence weakened them. The timeline should be read with the evaluation checklist, not as a list of heroes and villains. For your own research, use the timeline builder.